Rochelle Maher

3.1k total citations
19 papers, 663 citations indexed

About

Rochelle Maher is a scholar working on Infectious Diseases, Epidemiology and Small Animals. According to data from OpenAlex, Rochelle Maher has authored 19 papers receiving a total of 663 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 10 papers in Epidemiology and 5 papers in Small Animals. Recurrent topics in Rochelle Maher's work include Antifungal resistance and susceptibility (10 papers), Fungal Infections and Studies (8 papers) and Infectious Diseases and Mycology (5 papers). Rochelle Maher is often cited by papers focused on Antifungal resistance and susceptibility (10 papers), Fungal Infections and Studies (8 papers) and Infectious Diseases and Mycology (5 papers). Rochelle Maher collaborates with scholars based in United States, Germany and Switzerland. Rochelle Maher's co-authors include Oliver A. Cornely, Luis Ostrosky‐Zeichner, John R. Perfect, John R. Wingard, William E. Fitzsimmons, Donna Przepiorka, Laura Kovanda, Joseph W. Fay, Richard A. Nash and Lynn A. Drake and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Clinical Infectious Diseases.

In The Last Decade

Rochelle Maher

19 papers receiving 639 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rochelle Maher United States	12	303	282	176	131	113	19	663
Anna Cäcilia Ingham Denmark	12	51 0.2×	70 0.2×	135 0.8×	72 0.5×	37 0.3×	24	424
Claire L. Fellman United States	11	102 0.3×	39 0.1×	26 0.1×	11 0.1×	74 0.7×	24	376
Tricia Heaton Australia	10	118 0.4×	38 0.1×	66 0.4×	136 1.0×	7 0.1×	14	664
P. Höger Germany	14	148 0.5×	93 0.3×	246 1.4×	112 0.9×	31 0.3×	65	586
Edgardo Chouela Argentina	13	133 0.4×	185 0.7×	196 1.1×	30 0.2×	29 0.3×	38	599
Michal Solomon Israel	18	220 0.7×	93 0.3×	154 0.9×	102 0.8×	97 0.9×	42	955
M. J. Boffa United Kingdom	13	97 0.3×	158 0.6×	145 0.8×	31 0.2×	37 0.3×	21	538
Robert B. Skinner United States	13	273 0.9×	53 0.2×	233 1.3×	28 0.2×	19 0.2×	39	637
Chad W. Dunaway United States	16	198 0.7×	240 0.9×	31 0.2×	47 0.4×	14 0.1×	18	794
Ayşen Uğuz Türkiye	9	197 0.7×	142 0.5×	40 0.2×	133 1.0×	27 0.2×	17	672

Countries citing papers authored by Rochelle Maher

Since Specialization

Citations

This map shows the geographic impact of Rochelle Maher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rochelle Maher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rochelle Maher more than expected).

Fields of papers citing papers by Rochelle Maher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rochelle Maher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rochelle Maher. The network helps show where Rochelle Maher may publish in the future.

Co-authorship network of co-authors of Rochelle Maher

This figure shows the co-authorship network connecting the top 25 collaborators of Rochelle Maher. A scholar is included among the top collaborators of Rochelle Maher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rochelle Maher. Rochelle Maher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Marón, Gabriela, Michael Boeckh, Genovefa A. Papanicolaou, et al.. (2025). P-103. Adenoviremia Clearance Following Treatment with Intravenous (IV) Brincidofovir (BCV) in Immunocompromised Patients is Associated with Positive Clinical Disease Response: Preliminary Outcomes from the ATHENA Phase IIa Study. Open Forum Infectious Diseases. 12(Supplement_1). 1 indexed citations

Bhandari, Sahil, Karen Xie, Rochelle Maher, et al.. (2024). Odor, air quality, and well-being: understanding the urban smellscape using crowd-sourced science. SHILAP Revista de lepidopterología. 2(3). 35012–35012. 3 indexed citations

Eykelbosh, Angela, et al.. (2021). Elucidating the community health impacts of odours using citizen science and mobile monitoring. 64(2). 24–27. 8 indexed citations

Perfect, John R., Oliver A. Cornely, M. Heep, et al.. (2018). Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. Mycoses. 61(7). 420–429. 24 indexed citations

Cornely, Oliver A., Kathleen M. Mullane, Luis Ostrosky‐Zeichner, et al.. (2018). Isavuconazole for treatment of rare invasive fungal diseases. Mycoses. 61(8). 518–533. 34 indexed citations

Marty, Francisco M., Oliver A. Cornely, Kathleen M. Mullane, et al.. (2018). Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses. 61(7). 485–497. 31 indexed citations

Thompson, George R., Adrián Rendón, Rodrigo Ribeiro dos Santos, et al.. (2016). Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. Clinical Infectious Diseases. 63(3). 356–362. 139 indexed citations

Kovanda, Laura, Rochelle Maher, & William Hope. (2016). Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis. Expert Review of Clinical Pharmacology. 9(7). 887–897. 15 indexed citations

Marty, Francisco M., John R. Perfect, Oliver A. Cornely, et al.. (2014). 824An Open-Label Phase 3 Study of Isavuconazole (VITAL): Focus on Mucormycosis. Open Forum Infectious Diseases. 1(suppl_1). S235–S236. 21 indexed citations

10.

Raad, Issam, Kathleen M. Mullane, Dominik Selleslag, et al.. (2014). 825A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole vs Voriconazole in Patients with Invasive Mold Disease (IMD): Outcomes in Patients with Pulmonary Infections. Open Forum Infectious Diseases. 1(suppl_1). S236–S236. 4 indexed citations

11.

Vehreschild, Maria J. G. T., Jörg Janne Vehreschild, Francisco M. Marty, et al.. (2014). Primary Treatment of Invasive Mucormycosis (IM) with Isavuconazole (VITAL Study) or Amphotericin Formulations (FungiScope™): Case Matched Analysis. Blood. 124(21). 1151–1151. 3 indexed citations

12.

Patterson, Thomas F., Dominik Selleslag, Kathleen M. Mullane, et al.. (2014). 1210A Phase 3, Randomized, Double-Blind, Non-inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Neutropenic Patients. Open Forum Infectious Diseases. 1(suppl_1). S36–S37. 1 indexed citations

13.

Kontoyiannis, Dimitrios P., Michael Giladi, Misun Lee, et al.. (2014). 1211A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Invasive Aspergillosis Patients. Open Forum Infectious Diseases. 1(suppl_1). S37–S37. 10 indexed citations

14.

Fleischer, Alan B., Mark Ling, Lawrence F. Eichenfield, et al.. (2002). Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. Journal of the American Academy of Dermatology. 47(4). 562–570. 82 indexed citations

15.

Drake, Lynn A., Mary M. Prendergast, Rochelle Maher, et al.. (2001). The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. Journal of the American Academy of Dermatology. 44(1). S65–S72. 109 indexed citations

16.

Horowitz, Mary M., Donna Przepiorka, Pamela Bartels, et al.. (1999). Tacrolimus vs. cyclosporine immunosuppression: Results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. Biology of Blood and Marrow Transplantation. 5(3). 180–186. 23 indexed citations

17.

Przepiorka, Donna, Richard A. Nash, John R. Wingard, et al.. (1999). Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biology of Blood and Marrow Transplantation. 5(2). 94–97. 64 indexed citations

18.

Wingard, John R., Richard A. Nash, Donna Przepiorka, et al.. (1998). Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biology of Blood and Marrow Transplantation. 4(3). 157–163. 60 indexed citations

19.

Devine, Steve, RB Geller, Liming Lin, et al.. (1997). The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.. PubMed. 3(1). 25–33. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact